<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=Something_You_Haven%27t_Heard_About_INPP5D</id>
		<title>Something You Haven't Heard About INPP5D - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=Something_You_Haven%27t_Heard_About_INPP5D"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=Something_You_Haven%27t_Heard_About_INPP5D&amp;action=history"/>
		<updated>2026-06-25T13:46:05Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=Something_You_Haven%27t_Heard_About_INPP5D&amp;diff=95877&amp;oldid=prev</id>
		<title>Cloth59butter : Page créée avec « 4A). Additionally, IL-1-ra reduced serum IL-1�� compared with untreated CNTg mice (Fig. 4B; P [http://www.selleckchem.com/products/RO4929097.html find more] We next so... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=Something_You_Haven%27t_Heard_About_INPP5D&amp;diff=95877&amp;oldid=prev"/>
				<updated>2017-04-30T18:28:33Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « 4A). Additionally, IL-1-ra reduced serum IL-1�� compared with untreated CNTg mice (Fig. 4B; P [http://www.selleckchem.com/products/RO4929097.html find more] We next so... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;4A). Additionally, IL-1-ra reduced serum IL-1�� compared with untreated CNTg mice (Fig. 4B; P [http://www.selleckchem.com/products/RO4929097.html find more] We next sought to determine the upstream signalling mechanisms behind IL-1�� processing and release in calcineurin-transgene-induced heart failure. To this end, CNTg mice were bred into the Nlrp3?/? background. Mean echocardiographic measurements are presented in Table 2. Similar to IL-1-ra treatment, we observed an improvement in left ventricular systolic performance in Nlrp3?/? CNTg mice. Fractional shortening was 50 �� 6% in Nlrp3?/? CNTg mice, compared with 33 �� 3% in CNTg mice (Fig. 5B; P [http://en.wikipedia.org/wiki/INPP5D INPP5D] of maintained myocyte organization and structure, and a reduced mononuclear cellular infiltrate. We assessed activation of the inflammasome in Nlrp3?/? CNTg hearts by Western blotting and serum analysis. Genetic deletion of Nlrp3 produced no changes in ASC or pro-caspase-1 expression (Fig. 6A); however, there was a significant reduction in serum-IL-1�� in Nlrp3?/? CNTg mice compared with CNTg mice (Fig. 6B; P [http://www.selleckchem.com/products/Nutlin-3.html learn more] with serum IL-1�� measurements, myocardial activation of pro-caspase-1 was reduced in Nlrp3?/? CNTg hearts, suggesting that IL-1�� intracellular processing occurs downstream of Nlrp3-dependent caspase-1 activation (Fig. 6A). In addition to IL-1�� reduction, Nlrp3?/? CNTg mice had significantly reduced serum TNF-�� compared with CNTg mice (Fig. 6C), consistent with a reduction in systemic inflammation on Nlrp3 and IL-1�� antagonism. We have previously assessed the role of inducible nitric oxide synthase signalling in the cardiac inflammation in CNTg mice, noting an improvement in cardiac structure and function with a resolution of inflammation on genetic ablation of inducible nitric oxide synthase (Somers et al. 2008). There is growing evidence to suggest that a significant component of IL-1��-induced cardiac dysfunction results downstream of inducible nitric oxide synthase (Tatsumi et al. 2000; Csont et al.&lt;/div&gt;</summary>
		<author><name>Cloth59butter</name></author>	</entry>

	</feed>